The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma
Open Access
- 1 May 2013
- journal article
- Published by Informa UK Limited in OncoImmunology
- Vol. 2 (5), e24270
- https://doi.org/10.4161/onci.24270
Abstract
Ovarian cancer is one of the neoplasms affecting the reproductive tract associated with high mortality rate because of limited therapeutic options and an elevated incidence of chemoresistance and recurrence. In this context, immunotherapy may constitute a promising approach to improve survival rates and clinical outcome, raising the need for specific target antigens. Cancer-testis antigens (CTAs) are considered promising candidates in this sense because they are aberrant expressed by various malignancies but not by non-transformed tissue, with the exception of testes. Here, we examined the expression and potential to promote humoral immune responses of a novel CTA, A-kinase anchor protein 4 (AKAP4), among 38 ovarian carcinoma patients. Our results reveal that AKAP4 was expressed at both the mRNA and protein levels in 89% (34/38) of ovarian carcinoma tissue specimens but not in 21 matched adjacent non-cancerous tissues. In addition, a humoral response against AKAP4 was detected in 58% (22/38) of ovarian carcinoma patients by ELISA. In particular, 65% (22/34) patients bearing an AKAP4-expressing tumor exhibited circulating anti-AKAP4 antibodies. Interestingly, the majority of specimens were categorized as ovarian serous adenocarcinoma and serous papillary carcinoma, of which 93% (28/30) and 100% (6/6), respectively, expressed AKAP4. A humoral response against AKAP4 was detected in 79% (19/24) and 67% (4/6) of ovarian serous adenocarcinoma and serous papillary carcinoma patients, respectively. The presence of circulating anti-AKAP4 antibodies suggests the AKAP4 is highly immunogenic in ovarian serous carcinoma patients. Our study lays the foundations for exploring AKAP4 as a potential target for the immunotherapy of ovarian cancer.Keywords
This publication has 28 references indexed in Scilit:
- Cancer testis antigensOncoImmunology, 2012
- Identification of AKAP‐4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancerThe Prostate, 2011
- Sperm-Associated Antigen 9 Is a Novel Biomarker for Colorectal Cancer and Is Involved in Tumor Growth and TumorigenicityThe American Journal of Pathology, 2011
- Cancer Testis Antigen Vaccination Affords Long-Term Protection in a Murine Model of Ovarian CancerPLOS ONE, 2010
- Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian CancerClinical and Developmental Immunology, 2010
- Sperm‐associated antigen 9 is a biomarker for early cervical carcinomaCancer, 2009
- Sperm-Associated Antigen 9 Is Associated With Tumor Growth, Migration, and Invasion in Renal Cell CarcinomaCancer Research, 2008
- AKAP‐4: a novel cancer testis antigen for multiple myelomaBritish Journal of Haematology, 2008
- Sperm-Associated Antigen 9, a Novel Cancer Testis Antigen, Is a Potential Target for Immunotherapy in Epithelial Ovarian CancerClinical Cancer Research, 2007
- Molecular Cloning of Human Testis mRNA Specifically Expressed in Haploid Germ Cells, Having Structural Homology with the A-Kinase Anchoring ProteinsBiochemical and Biophysical Research Communications, 1998